2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nageshwara Arvind Dasari, MD, discusses the eligibility criteria for the phase 3 FRESCO-2 trial, which examined the use of fruquintinib in patients with metastatic colorectal cancer.
Nageshwara Arvind Dasari, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the eligibility criteria for the phase 3 FRESCO-2 trial (NCT04322539), which examined the use of fruquintinib in patients with metastatic colorectal cancer (CRC).
Patients who have documented advanced CRC who have previously received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, in addition to an anti-VEGF agent, will be included on the FRESCO-2 trial, according to Dasari. If a patient had RAS wild-type disease, they should have received a prior anti-EGFR therapy, while those who are microsatellite instability high should have received immunotherapy and those with BRAF-mutant disease needed to have received a BRAF-targeted agent, Dasari explains.
Additionally, in order to enroll on the study, patients needed to have experienced progression on, or intolerance to, trifluridine and tipiracil (Lonsurf) and/or regorafenib (Stivarga), Dasari concludes.